Menu

Headquartered at the medical center’s Mount Zion campus in San Francisco, California, the Helen Diller Family Comprehensive Cancer Center is the renowned cancer treatment arm of the University of California San Francisco Medical Center (UCSF). Named after a Bay Area philanthropist, the Helen Diller Cancer Center brings together scientists and clinicians from a wide spectrum of backgrounds with one shared goal: preventing and eradicating cancer. Its success has been notable.

A key figure in the history of UCSF’s cancer care was David A. Wood, a respected doctor who served as the first director of the UCSF Cancer Research Institute starting in 1948. Wood brought to his position a belief that to cure cancer, the medical community must take a “multidisciplinary approach, both clinical and basic scientists working together.” This philosophy remains central to the hospital’s beliefs today.

In 1999, UCSF’s cancer center was designated a “comprehensive cancer center” by the National Institutes of Health, the highest possible designation bestowed by the government agency. The title recognized the center for its scientific excellence, diverse research tactics, excellent patient care, and effective outreach activities that seek to prevent as well as control cancer. In 2007, the UCSF cancer center was renamed as the UCFS Helen Diller Family Comprehensive Cancer Center, paying tribute to support from Bay Area resident Helen Diller and her family.

The University of California San Francisco at Mount Zion fully understands diagnosing and treating mesothelioma. They take a careful approach to develop treatment plans unique to the patient’s situation and type of mesothelioma. Patients seeking treatment at this cancer center can also undergo clinical trials.

Specializations:

  • Clinical trials
  • Standard and experimental mesothelioma treatments

Mesothelioma Clinical Trials at University of California San Francisco at Mount Zion

The following clinical trials are in progress or actively recruiting participants at University of California San Francisco at Mount Zion:

Sorry, there are no clinical trials to display

Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin


Conditions: Mesothelioma

Last Updated: September 18, 2019

Status: Recruiting

Photo of University of California San Francisco at Mount Zion

Get Help Contacting University of California San Francisco at Mount Zion


    Privacy policy: All information is secure and will never be released

    TRUSTe

    Free

    Mesothelioma Treatment Guide

    Please fill in the form to request our FREE Mesothelioma Treatment Guide.
    It will be sent to you within 24 hours.

    Free Mesothelioma Treatment Guide



      Privacy policy: All information is secure and will never be released

      TRUSTe